Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Merck and Moderna sign cancer vaccine deal
by Ryan Cross
May 13, 2018
| A version of this story appeared in
Volume 96, Issue 20
Merck & Co. is expanding its partnership with the mRNA company Moderna Therapeutics. Merck will make a $125 million investment into the Cambridge, Mass.-based biotech and begin clinical tests of a Moderna cancer vaccine. The vaccine is designed to stimulate the immune system to spot and destroy cancer cells that have any of the four most common mutations of a protein called KRas, which is one of cancer’s toughest drug targets, found in about 30% of all tumors. Merck is eager to test the vaccine in combination with its checkpoint inhibitor immunotherapy Keytruda.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X